Gilead Sciences, Inc.
吉利德科学NASDAQ: GILDBiopharma · Virology & Oncology · US-listed
Biopharmaceutical company known for HIV/liver-disease therapies and growing oncology portfolio.
Filings
Quarterly results press releaseQuarter ended Jun 30, 2026 (Q2 2026)Filed 2026-08-04
Gilead Sciences Announces Second Quarter 2026 Financial ResultsQ2 total revenues $7.8B (+10% YoY); product sales ex-Veklury +10% to $7.6B. GAAP diluted loss per share $(8.45) and non-GAAP $(6.75) driven by $11.2B acquired IPR&D and $1.75B IPR&D impairment; HIV product sales +12% to $5.7B, Biktarvy +7% to $3.8B.
Total revenues: $7.8B (+10% YoY)HIV product sales: $5.7B (+12% YoY)GAAP diluted EPS: $(8.45) (incl. $11.2B acquired IPR&D)Non-GAAP diluted EPS: $(6.75)
Where to download Gilead Sciences, Inc. filings
US filings live on SEC EDGAR: annual reports (10-K), quarterly reports (10-Q) and earnings press releases (8-K Exhibit 99.1) are all in the company EDGAR archive; each filing page above links to the exact filing. You can also check the investor relations page.